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Abstract
Acute kidney injury (AKI) is one of the most important complications during hospitaliza-
tion, especially in critically ill patients. Recent data demonstrated that certain biomarkers 
including pro-inflammatory cytokines are associated with high morbidity and mortality. 
These biomarkers, most of which have middle molecular weight, and protein-bound ure-
mic toxins are limitedly removed by diffusion mechanism in conventional hemodialysis. 
Hemodiafiltration (HDF), a new modality that combines convective clearance with diffu-
sion, could effectively enhance removal of middle molecule and protein-bound solutes. 
Therefore, HDF is increasingly used in several AKI settings such as septic AKI, rhab-
domyolysis-associated AKI, myeloma cast nephropathy, and contrast-induced AKI. This 
chapter summarizes the available HDF techniques including intermittent and continuous 
modes, and clinical data comprise the benefits of HDF on biomarkers and renal as well as 
cardiovascular outcomes. Additionally, the topic provides the proposed future directions 
of HDF in various AKI settings.
Keywords: acute kidney injury, hemodiafiltration, convection, diffusion, sepsis, 
rhabdomyolysis, myeloma
1. Background
Acute kidney injury (AKI) is one of the most serious complications of patients during 
hospitalization especially in critically ill patients [1]. The annual incidence and mortality 
of AKI have been escalating despite much improvement of patient cares [2]. Besides cor-
recting the underlying causes of AKI, there is no specific medication for effective treatment 
of AKI. Nowadays, the main treatment of AKI is still limited to supportive management. 
However, some patients had refractory volume overload and severe metabolic derangement; 
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therefore, renal replacement therapy (RRT) has become a key management in patients with 
AKI and multi-organ failure in order to normalize fluid, electrolyte, and acid–base status. 
Hemodiafiltration (HDF), one of the recently innovative RRT modalities, could provide ben-
efits in decreasing inflammatory markers and cytokines, which play an important role in 
various AKI entities.
2. Principles of renal replacement therapy (RRT)
There are two main transportation processes of solutes and fluid across a membrane during 
RRT, diffusion and convection [3].
2.1. Diffusion
Diffusion is the process of spontaneous migration of solutes from a higher concentration to 
a lower concentration across the semipermeable membrane until the concentration becomes 
equal throughout a space (Figure 1). Factors affecting diffusion are concentration gradients, 
molecular size and charge of the solutes, surface area, thickness, and solute permeability of 
the membrane. Diffusion is the main determinant mechanism of small solute clearance in 
hemodialysis (HD).
Figure 1. The processes of diffusion (top) and convection (bottom):  = Small solutes;  = Middle molecule and protein-
bound solutes;  = Large solutes.
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2.2. Convection (solvent drag)
Convection is the transportation process which the solutes migrate along with water flow 
(solvent) across the semipermeable membrane (Figure 1). Water flow or ultrafiltration is the 
movement of fluid across the membrane produced by transmembrane pressure gradients. 
There are many factors affecting the convection such as solute concentration gradients, 
sieving coefficient, surface area, pore size, and the permeability of membrane, but the most 
important one is ultrafiltration rate. Convection is able to remove protein-bound uremic tox-
ins and middle molecule solutes such as interleukins, complement, platelet-activating factors, 
and other cytokines. This process is the main determinant mechanism of solute clearance in 
hemofiltration (HF).
3. HDF techniques
HDF is an RRT modality which combines diffusion and convection techniques to enhance 
the removal of middle molecule solutes and protein-bound uremic toxins by using high-
flux dialyzer [4]. Therefore, this technique requires not only dialysate fluid but also sterile 
substitution fluid for replacement. There are various types of dilutional methods accord-
ing to the site of replacement fluid infusion pre-dilution, post-dilution, mid-dilution, and 
mixed-dilution.
3.1. Pre-dilution HDF
In pre-dilution HDF, the replacement fluid is infused before the dialyzer (Figure 2A). Pre-
dilution infusion reduces hemoconcentration across the membrane leading to prolongation 
of the extracorporeal circuit duration. However, this method provides less efficiency of solute 
clearance by diffusion.
3.2. Post-dilution HDF
Post-dilution HDF is the most efficient solute removal method of HDF due to high concentra-
tion gradient between blood and dialysate fluid. In post-dilution method, the replacement 
fluid is infused downstream the dialyzer (Figure 2B). An important disadvantage is that the 
increased hemoconcentration during high ultrafiltration rates would result in clogging of the 
membrane pores. Occlusion of the dialyzer leads to high transmembrane pressure gradient, 
reducing solute clearance, and, eventually, membrane leakage or clotting in the dialyzer.
3.3. Mid-dilution HDF
The replacement fluid is infused between two high-flux dialyzers placed in series resulting 
in a first post-dilution hemodiafiltration stage followed by a pre-dilution hemodiafiltration 
stage (Figure 2C). This technique can combine the advantage of both pre-dilution and post-
dilution. However, the high transmembrane pressure and clotting in the first part of dialyzer 
are the important limitation of this technique.
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3.4. Mixed-dilution HDF
The replacement fluid is infused both before and after the dialyzer (Figure 2D). To reduce 
the unfavorable components of pre- and post-dilution HDF, the ratio of upstream and down-
stream infusion rates can be adjusted to achieve the optimal balance between maximizing 
clearance and avoiding hemoconcentration.
Of note, the efficacy of convection transport mainly depends on convection volume which con-
sists of replacement fluid and ultrafiltration fluid. The classic HDF technique requires approxi-
mately 10 L of replacement fluid per session, while high-volume HDF uses at least 15 L per 
session for greater convection transport. Online HDF (OL-HDF) has been developed to reduce 
the high cost of commercial replacement fluid. OL-HDF is a technique using the dialysis fluid 
itself as the replacement fluid. After multiple steps of water purification process, the dialysis 
fluid becomes ultrapure before the final filtration and the last ultrafilter must have the capacity 
to create sterile substitutional fluid. This technique contributes a very high fluid turnover of 
25–30 L per session and significantly improves middle molecule solute clearance [5, 6].
In summary, HDF has higher potency of removal of middle molecule solutes and protein-
bound uremic toxins than the conventional HD [7]. Therefore, HDF would provide more 
benefits than conventional HD in patients with AKI particularly in certain situations, such as 
sepsis, rhabdomyolysis, and myeloma cast nephropathy, which requires more middle mol-
ecule solute clearance.
Figure 2. HDF modes according to the site of replacement fluid infusion: pre-dilution (A), post-dilution (B), mid-dilution 
(C), and mixed-dilution (D).
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4. HDF and sepsis-induced AKI
Sepsis is the most common cause of AKI in critically ill patients. A line of evidence shows that 
AKI may occur in the absence of overt hemodynamic instability. The novel concepts in the 
pathophysiology of sepsis-induced AKI are explained by several mechanisms, including inflam-
mation, alteration of microcirculatory flow, and cellular responses to the inflammatory insults 
(Figure 3) [8, 9].
Firstly, the pro-inflammatory cytokines produced in sepsis such as tumor necrosis factor 
(TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon (IFN) could contribute direct 
renal tubular injury [10]. In addition to the large amount of pro-inflammatory cytokines, nitric 
oxide and vascular endothelial growth factor (VEGF) generated during sepsis are respon-
sible for the distortion of renal microcirculation and endothelial dysfunction [11], even with 
normal or increased global renal blood flow [12]. These alterations provide heterogeneity 
of regional blood flow distribution, impair renal autoregulation, and finally promote renal 
dysfunction [13, 14]. At the cellular level, mitochondria is the common target of inflammatory 
injury, which leads to its dysfunction, increased production of reactive oxygen species (ROS), 
and cell cycle arrest [15, 16].
According to these mechanisms, hemodynamic compromise does not seem to be very sig-
nificant to deteriorate renal function. A previous study demonstrated that hypotension does 
not correlate with AKI in patients with severe sepsis [17]. Meanwhile, the production of cyto-
kines, nitric oxide, and ROS may be the key pathogenesis of sepsis-induced AKI. Moreover, 
prolonged release of inflammatory mediators leads to severely impaired immunity which 
is followed by the secondary infection [18]. Therefore, this immunoparalysis state plays an 
important role in the mortality of patients with sepsis. Restoration of immune homeostasis 
might be able to improve the outcomes [19].
Figure 3. Pathophysiology of sepsis-induced AKI. Abbreviation: ROS, reactive oxygen species; TNF, tumor necrosis 
factor; IL-1, interleukin-1; IL-6, interleukin-6.
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Theoretically, HDF could provide significantly higher middle molecule clearance including 
pro-inflammatory cytokines when compared with conventional HD. Therefore, many stud-
ies have tried to determine the benefits of HDF in sepsis-induced AKI. Indeed, a number of 
theories trying to explain the effects of blood purification have been proposed. First, Ronco 
et al. postulated that eliminating the peaks of cytokine concentration from the blood circulation 
during the early phase of sepsis could stop the inflammatory cascade, limit organ damage, and 
consequently decrease multi-organ failure [20]. The second concept is called “threshold immu-
nomodulation hypothesis.” Honore et al. proposed that cytokine removal affects not only the 
cytokine concentrations in bloodstream but also the level in tissues [21]. This is caused by an 
equilibration of their concentrations between the two compartments. According to this hypoth-
esis, cytokines for the tissues replace those removed from the blood. Hence, no significant 
reduction in bloodstream cytokine concentration is observed during blood purification. The 
third concept is about immunomodulation. During blood purification therapy, the inflamma-
tory cell could restore the immune function through the regulation of monocytes, neutrophils, 
and lymphocytes [22]. HF and HDF could play a role at this point by reducing a large amount 
of cytokines, terminating the inflammatory cascade, and promoting the immune recovery. 
However, the benefits of these modalities have been demonstrated in only limited studies.
There have been several observational studies in critically ill patients with multiple organ failure 
demonstrating that high-volume HF (HVHF) which prescribed at least 35 mL/kg/hr. of ultrafil-
tration volume or intermittent HDF improved patients’ clinical outcomes [23–27]. Kron et al. per-
formed an extended daily online high-volume HDF (6–23 hours) with convective volume about 
173 L/treatment in patients with sepsis [28]. In this study, hemodynamics improved significantly 
during the treatment, and the 90-day survival rate compared with the survival rate predicted by 
severity scores (APACHE II and SAPS II) was 52 versus 19%. A previous prospective random-
ized controlled trial (RCT) in sepsis-induced AKI patients illustrated that pre-dilution intermit-
tent OL-HDF for 4 hours enhanced cytokine removal over intermittent high-flux HD [29]. The 
clearance and reduction ratio of either pro-inflammatory or anti-inflammatory cytokines such as 
IL-6 (26 kDa), IL-8 (8 kDa), IL-10 (40 kDa), VEGF (46 kDa), and TNF-a (51 kDa) was significantly 
greater in OL-HDF than high-flux HD modality. Moreover, OL-HDF showed some better clini-
cal outcomes including renal recovery and shorter length of hospital stay. Nevertheless, there 
was no significant difference in mortality between these two modalities. Another RCT, which 
compared every day or every alternate day of intermittent high-volume pre-dilution OL-HDF 
(the mean volume of replacement fluid is 81 L) to standard intermittent HD for 4 hours in criti-
cally ill ICU patients with AKI as part of multiple organ failure, failed to demonstrate the signifi-
cant difference in mortality and kidney function recovery [30].
Most of critically ill patients with septic shock or hemodynamic instability require continuous 
RRT (CRRT). In addition to the advantage in maintaining hemodynamic stability through 
slow continuous ultrafiltration, many studies have proposed its ability in removal of pro-
inflammatory cytokines and other middle molecule solutes through convection. Both contin-
uous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemofiltration 
(CVVH) could be performed to increase convective transport. A retrospective, longitudinal 
follow-up study for 12 months in severe sepsis with AKI patients who received CRRT includ-
ing CVVH and CVVHDF aiming at the dose of dialysis more than 35 mL/kg/hr. in ICU was 
performed [31]. There was no significant difference in survival rate between sepsis-induced 
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AKI patients treated with CVVH and CVVHDF. However, subgroup analysis in patients with 
oliguria/anuria showed significantly higher survival in patients treated with CVVHDF com-
pared with CVVH. However, this result could actually be explained by the effect of residual 
renal clearance. In patients who still preserved diuresis, some pro-inflammatory cytokines 
were removed from plasma into the urine. Therefore, different CRRT modes might not 
affect the clinical outcomes. On the other hand, after loss of renal function, a large number 
of cytokines were more rapidly accumulated. A combination of diffusion and convection by 
CVVHDF might better control the cytokines and other uremic toxin accumulations and pro-
vided better survival outcome. However, this hypothesis needs further investigations.
4.1. Dose prescription
Besides the modalities of CRRT, the CRRT dose utilized for sepsis-induced AKI is still 
unestablished. Prescribed and delivered doses of CRRT in AKI vary widely. Two large, mul-
ticenter RCTs were conducted in critically ill patients with AKI to investigate the effects of 
RRT dose on survival benefit. The US Department of Veterans Affairs/National Institutes of 
Health conducted Acute Renal Failure Trial Network (ATN) study by randomly assigning 
1124 critically ill patients with AKI who required RRT to high-intensity RRT (35 mL/kg/hr. 
of pre-dilution CVVHDF or six sessions per week of SLEDD/IHD) or low-intensity RRT 
(20 mL/kg/hr. of pre-dilutional CVVHDF or three sessions per week of SLEDD/IHD) [32]. 
The results showed survival rates after 60 days of 46% in high-intensity group and 48% in 
low-intensity group (p value = 0.47). In another RCT trial, the Randomized Evaluation of 
Normal versus Augmented Level (RENAL) of Replacement Therapy study of 1508 critically 
ill patients meeting the criteria for initiation RRT was included and randomly assigned to 
post-dilution CVVHDF with effluent rate of 40 or 25 mL/kg/hr [33]. There was no statistically 
significant difference of 90-day mortality between high- and low-dose RRT groups. Moreover, 
the secondary outcomes such as length of ICU and hospital stay, duration of mechanical 
ventilation therapy, and dialysis status at 90 days were not different. Both studies failed to 
demonstrate any benefits of using high-intensity RRT. Although the higher doses of CRRT 
are expected to provide more effective inflammatory cytokine removal in sepsis, subgroup 
analysis of patients with sepsis or organ failure revealed no significant differences in the mor-
tality between the high- and low-intensity RRT. In addition, a recent prospective study in 
sepsis-induced AKI patients failed to demonstrate improvement in clinical outcomes of the 
high-dose pre-dilution CVVHDF over the conventional dose (80 vs. 40 mL/kg/hr) despite 
significant influence of high-dose CVVHDF in removal of IL-6, IL-8, and IL-10 [34]. Therefore, 
the KDIGO guidelines [35] proposed the optimal dose of CRRT of 20–25 mL/kg/hr in patients 
with AKI regardless of the etiologies of AKI. The studies examining the effects of RRT dose 
and outcomes are summarized in Table 1. However, delivering of the prescribed dose may be 
compromised due to filter clotting, concentration polarization of the filter, and other factors 
including access-related problems which diminish the treatment time. Rolando et al. studied 
the actual delivered dose of RRT in critically ill patients with AKI requiring dialysis. The 
delivered clearance was derived from the ratio of mass removal rate to blood concentration 
and effluent volume rate. From this study, the prescribed clearance overestimated the actual 
delivered clearance by 23.8% [36]. Therefore, the effluent rate prescription should be increased 
by 20–25% to achieve an actual prescribed dose.
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Author/study Type Sample Comparison/intervention Outcomes
Comparing HDF and other modalities
Dario et al. [23] Multicenter, 
prospective, and 
comparative study
65 patients 
with AKI and 
sepsis
OL-HDF versus low-
intensity high-flux IHD
OL-HDF showed 
benefits statistically 
significant in intensive 
care unit stay
Chancharoenthana 
et al. [29]
Single-center RCT 28 patients 
with AKI and 
sepsis
OL-HDF versus high-flux 
IHD
OL-HDF showed 
significant higher 
inflammatory cytokine 
removal, better renal 
recovery, and shorter 
length of hospital stay
Skofic et al. [30] Single-center RCT 273 critically ill 
patients with 
AKI
High-volume OL-HDF 
(mean volume 81 L) 
versus
standard IHD
No significant 
difference of mortality
Premuzic et al. [31] Retrospective, 
longitudinal follow-up 
study for 12 months 
duration
137 patients 
with AKI and 
sepsis
CVVHDF versus CVVH 
aiming at the dose of 
dialysis >35 mL/kg/hr
No significant 
difference in survival 
rate
Subgroup analysis in 
patients with oliguria/
anuria showed 
significantly higher 
survival in patients 
treated with CVVHDF 
compared with CVVH
Effect of HDF dose and outcomes
Kron et al. [28] Prospective 
observational study
21 patients 
with AKI and 
sepsis
Extended daily online 
high-volume HDF 
(6–23 hours) with 
convective volume 
about 173 L/treatment in 
patients with sepsis
Significantly lower 
predicted mortality by 
APACHEII and SAPSII 
scores
ATN trial [32] Multicenter RCT 1124 critically 
ill patients 
with AKI
Pre-dilution CVVHDF 
35 ml/kg/r or six sessions/
week of SLEDD/IHD 
versus pre-dilution 
CVVHDF 20 ml/kg/hr or 
three sessions/week of 
SLEDD/IHD
No significant 
difference of survival 
rate (46 and 48%)
RENAL trial [33] Multicenter RCT 1508 critically 
ill patients 
with AKI
Post-dilution CVVHDF 
40 ml/kg/hr versus 25 ml/
kg/hr
No significant 
difference of survival 
rate (55 and 55%)
Park et al. [34] Single-center RCT 212 patients 
with AKI and 
sepsis
High-dose pre-dilution 
CVVHDF 80 mL/kg/hr 
versus conventional dose 
pre-dilution CVVHDF 
40 mL/kg/hr
Significant influence 
of high-dose CVVHDF 
in removal of 
inflammatory cytokines
No significant difference 
of mortality
Table 1. Clinical trials using HDF in critically ill patients with AKI.
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5. HDF and rhabdomyolysis-induced AKI
Myoglobin is an oxygen-binding protein found in cardiac and skeletal muscle. It has a molec-
ular mass of 17.9 kDa. In patients with normal renal function, a rapid rise in blood myoglobin 
levels would be followed by a rapid disappearance within 6 hours due to high renal clear-
ance. Myoglobin clearance decreases in renal impairment and myoglobin elimination half-life 
could be extended to 21 hours (range 17–29 hours) in dialyzed patients [37].
In rhabdomyolysis, myoglobin, released from injured muscle into circulation, induces renal 
vasoconstriction, oxidative stress, direct tubular injury, and tubular obstruction. Besides pro-
moting urine and renal clearance of myoglobin, effective removal by extracorporeal therapies 
might reduce renal injuries [38]. High-flux membranes typically allow clearance of molecules 
up to 20 kDa, while high cutoff (HCO) membranes permit molecules with 20–50 kDa. Some 
larger molecules such as albumin (65 kDa) and clotting factors may also be removed when 
convection is applied in HCO.
There was a case series reporting on HDF with a HCO membrane applied in the treatment 
of acute myoglobinuric renal failure [39]. Highly efficient myoglobin removal was demon-
strated. By measuring myoglobin content in the collected effluent, the single HCO-HDF for 
12 hours resulted in nearly 5 grams of myoglobin removal, with a mean myoglobin clearance 
of 80.7 mL/min. However, a high rebound in serum myoglobin on average to 244% of the 
post-procedure myoglobin level was observed. Several studies also reported mass myoglo-
bin removal on CVVHF with high-flux or HCO membranes [40–43]. However, there was no 
strong evidence displaying the effects of myoglobin removal on renal recovery and mortality 
outcome in myoglobinuric renal failure patients.
6. HDF and myeloma cast nephropathy
AKI in patients with multiple myeloma is mostly related to myeloma cast nephropathy char-
acterized by monoclonal light chain and uromodulin obstructions in distal tubules of the 
kidney. Cast nephropathy is generated by massive light chain secretion in the tubules and 
precipitated with reduction of tubular flow. There was an RCT comparing between intensive 
HD (eight 5-hour sessions over 10 days) with a HCO dialyzer (HCO-HD) and conventional 
HD among patients who were newly diagnosed with myeloma cast nephropathy and treated 
with a bortezomib-based chemotherapy regimen [44]. HCO-HD allowed higher clearance 
of both kappa (κ) and lambda (λ) light chains. Moreover, a rapid reduction of circulating 
monoclonal light chains by intensive HCO-HD resulted in a statistically significant difference 
in HD independence at 6 and 12 months (56.5 vs. 35.4%; p = 0.04 and 60.9 vs. 37.5%; p = 0.02, 
respectively). However, the HD-independent rate at 3 months which was the primary out-
come was not significantly different. Although using HCO membrane was likely to improve 
the renal outcome, higher albumin loss during HCO-HD should be considered.
Regarding HDF, there was a case series demonstrating the efficacy of supra-hemodiafiltration 
with endogenous reinfusion (supra-HFR) which is a subtype of HDF that utilizes separated 
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convection, diffusion, and adsorption [45]. The sorbent cartridge has a high affinity for both 
κ and λ free light chains without the drawback of albumin loss. In this report, more than 
50% reduction of the serum free light chain levels occurred within only 1 week of supra-HFR 
treatment, and three out of four cases became dialysis independent after 2–6 weeks with no 
significant loss of albumin.
7. HDF and contrast-induced nephropathy (CIN)
CIN is a common cause of AKI which can range from a minor or transient elevation of serum 
creatinine to severe renal failure requiring dialysis. These injuries are associated with signifi-
cant inhospital and long-term morbidity and mortality [46, 47]. Although various strategies 
in preventing CIN, such as acetylcysteine, theophylline, and other renoprotective drugs, have 
been evaluated, only intravenous administration of normal saline and sodium bicarbonate 
seem to be a useful method [48, 49].
Prophylactic HD starting immediately after administration of the contrast in patients with previ-
ous renal dysfunction failed to demonstrate the benefit in CIN prevention [50]. Nevertheless, 
Marenzi et al. reported the efficacy and safety of periprocedural CVVHF in chronic kidney 
disease patients undergoing coronary interventions (4–6 hours before coronary procedure and 
continued for 18–24 hours) [51]. The explanation for the discrepancy is that HD might induce 
hypovolemia, leading to renal hypoperfusion and renal ischemia which are important risk fac-
tors of CIN. On the contrary, CVVHF is corresponding with enhanced hemodynamic stability. In 
addition, CVVHF provides controlled high-volume hydration and could remove more contrast 
agent from the circulation, resulting in reduction of kidney exposure to the contrast agent. There 
was a study which compared the contrast media removing the ability of different extracorporeal 
treatments as low-flux HD, high-flux HD, HF, and HDF [52]. In this study, HDF and high-flux 
HD could effectively remove contrast media more effectively than low-flux HD and HF.
Katoh et al. performed HDF with blood suction from the right atrium (RA-HDF) in patients 
with renal dysfunction undergoing coronary angiography (CAG) or percutaneous coronary 
intervention (PCI) [53]. RA-HDF was started 30 minutes before the scheduled coronary pro-
cedure and continued until 30 minutes after the procedure. By this method, the blood was 
drawn from the right atrium near the orifice of the coronary sinus. Therefore, the contrast 
media injected into a coronary artery could be removed effectively before entering the sys-
temic circulation. Although there was no statistically significant difference, the frequency 
of CI-AKI was lower in the patients receiving normal saline hydration in combination with 
RA-HDF compared with those administered only normal saline (12 vs. 27%). Another study 
investigated the use of prophylactic HDF for 3 hours after emergency or urgent CAG in acute 
coronary syndrome patients with severe renal (eGFR <30 mL/min/1.73 m2) and cardiac dys-
functions (LVEF < 40%) [54]. Patients who were dialyzed with HDF had a lower incidence of 
severe AKI (10 vs. 40%) and lower requirement for RRT during hospitalization (7 vs. 27%). 
Moreover, they experienced significantly lower 1-year mortality rates than the controls. Taken 
together, prophylactic HDF is likely to provide salutary benefit in patients with very high 
risks who are undergoing coronary interventions. However, certain limitations should be 
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considered. First, these reports are prospective observational studies with quite small number 
of patients. Second, prophylactic HDF is associated with high expense, and the cost-effec-
tiveness should be evaluated. Table 2 details the comparison of outcomes between HDF and 
conventional HD in various AKI entities.
8. Conclusion
By combining diffusive and convective clearances, HDF is one of the most effective modalities 
in clearance of middle molecule solutes and protein-bound uremic toxins. In addition to the 
benefit of conventional uremic toxin clearance, HDF provides a significantly higher elimina-
tion of other nephrotoxic substances. This clearance capacity seems to be associated with the 
improvement of renal recovery and clinical outcomes in some special entities of AKI such as 
sepsis, rhabdomyolysis, myeloma cast nephropathy, and CIN. However, the reduction in the 
mortality of patients undergoing HDF is quite difficult to be evaluated. In conclusion, while 
there is rising of clinical evidence favoring HDF in AKI, further large-scale prospective RCTS 
are essentially required to confirm its benefits.
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Etiology of AKI HDF vs. conventional HD
Sepsis-induced AKI
Cytokine removal
Renal recovery
Mortality
Significantly higher cytokine removal than HD
Probable benefits
No benefit
Rhabdomyolysis Significantly higher myoglobin removal
No evidence of renal recovery and mortality benefit
Myeloma cast nephropathy Significantly higher free light chain removal
No evidence of renal recovery and mortality benefit
Prophylaxis of contrast-induced nephropathy Periprocedure HDF reduce incidence if CIN
Abbreviations: AKI: acute kidney injury; HDF: hemodiafiltration; HD: hemodialysis; CIN-AKI: contrast-induced 
nephropathy-acute kidney injury.
Table 2. Comparison of outcomes between HDF and conventional HD in various AKI settings.
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